STOCK TITAN

Aurora Cannabis (NASDAQ: ACB) schedules Q4 and FY 2026 call

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Aurora Cannabis Inc. will report its fourth quarter and fiscal year 2026 financial results and host an investor conference call on Thursday, June 11, 2026. The company plans to release results before markets open that day, followed by a call at 8:00 a.m. Eastern Time.

Chief Executive Officer Miguel Martin and Chief Financial Officer Simona King will lead the call and question-and-answer session. The announcement reiterates Aurora’s focus on global medical cannabis markets and includes standard forward-looking statement language referencing risk factors outlined in its June 17, 2025 annual information form.

Positive

  • None.

Negative

  • None.
Form 6-K regulatory
"FORM 6-K REPORT FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
forward-looking statements regulatory
"This news release includes statements containing certain "forward-looking information""
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
annual information form regulatory
"set out under the heading "Risk Factors" in the Company's annual information form dated June 17, 2025"
A company's annual information form is a comprehensive regulatory filing that lays out its business description, key assets, risks, legal matters and other background details shareholders need to understand the company’s operations. Think of it as a detailed owner’s manual or dossier that supplements financial statements, helping investors do deeper homework on how the business works and what could affect its future performance.
medical cannabis financial
"Aurora is a global leader in medical cannabis, dedicated to improving lives"
Medical cannabis is the use of cannabis plant extracts or compounds such as THC and CBD as prescribed or recommended to treat symptoms or medical conditions. Think of it as a plant-based medicine that can relieve pain, nausea, muscle spasms or other symptoms where conventional drugs may not work; for investors it matters because legal status, clinical evidence, supply rules and insurance coverage determine market size, licensing value and revenue potential.
GMP-certified manufacturing facilities technical
"With world-class GMP-certified manufacturing facilities in Canada and Germany"

 

 

  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File No. 001-38691

AURORA CANNABIS INC.
(Translation of registrant's name into English)

 

2207 90B St. SW
Edmonton, Alberta T6X 1V8
Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  ☐ Form 40-F  ☒

 

 

 
 

 

 

 

SUBMITTED HEREWITH

 

Exhibits Description 
99.1   News release dated May 28, 2026

 

 
 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AURORA CANNABIS INC.

/s/ Miguel Martin

 


Miguel Martin
Chief Executive Officer

Date: May 28, 2026

Exhibit 99.1 

 

 

 

 

 

 

Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2026 Investor Conference Call and File Related Year End Information

NASDAQ | TSX: ACB

EDMONTON, AB, May 28, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2026 on Thursday, June 11, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter and fiscal year 2026 before the opening of markets that same day.

 

Aurora Cannabis to host fourth quarter and fiscal year 2026 investor conference call

Conference Call Details

DATE: Thursday, June 11, 2026
TIME: 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time
WEBCAST: Click Here

 

Miguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".

About Aurora Cannabis

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™. 

Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing for the release of the Company's fourth quarter and fiscal year 2026 financial statements and the conference call to discuss the results.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-to-host-fourth-quarter-and-fiscal-year-2026-investor-conference-call-and-file-related-year-end-information-302783891.html

SOURCE Aurora Cannabis Inc.

 

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2026/28/c4918.html

%CIK: 0001683541

For further information: For Media: Michelle Lefler, VP, Communications & PR, media@auroramj.com; For Investors: ICR, Inc., Investor Relations, aurora@icrinc.com

CO: Aurora Cannabis Inc.

CNW 07:05e 28-MAY-26

FAQ

When will Aurora Cannabis (ACB) report Q4 and fiscal 2026 results?

Aurora Cannabis will report its fourth quarter and fiscal year 2026 results on Thursday, June 11, 2026, before markets open. The company will then host an investor conference call that morning to discuss the financial statements and address questions from participants.

What time is Aurora Cannabis’ Q4 and fiscal 2026 earnings call?

The Aurora Cannabis Q4 and fiscal 2026 investor conference call is scheduled for 8:00 a.m. Eastern Time, or 6:00 a.m. Mountain Time, on June 11, 2026. Investors can listen via the webcast link posted in the company’s Investor Info section under Events.

Who will host Aurora Cannabis’ fiscal 2026 investor conference call?

Chief Executive Officer Miguel Martin and Chief Financial Officer Simona King will host Aurora Cannabis’ fourth quarter and fiscal year 2026 conference call. They will present the financial results and lead a question-and-answer period with analysts and investors following the prepared remarks on June 11, 2026.

Where can investors access Aurora Cannabis’ Q4 2026 earnings webcast?

Investors can access the Aurora Cannabis Q4 and fiscal 2026 earnings webcast through a dedicated weblink referenced in the announcement. The link is also posted on the company’s website at auroramj.com, within the Investors section under the Events heading for convenient online access.

What forward-looking statements does Aurora Cannabis highlight in this update?

Aurora Cannabis notes forward-looking statements mainly about the timing of releasing its fourth quarter and fiscal 2026 financial statements and the related conference call. The company explains these statements rely on management assumptions and are subject to risks described in its June 17, 2025 annual information form.

Filing Exhibits & Attachments

1 document